成人小说亚洲一区二区三区,亚洲国产精品一区二区三区,国产精品成人精品久久久,久久综合一区二区三区,精品无码av一区二区,国产一级a毛一级a看免费视频,欧洲uv免费在线区一二区,亚洲国产欧美中日韩成人综合视频,国产熟女一区二区三区五月婷小说,亚洲一区波多野结衣在线

立即打開
這家生物科技公司力挺干細(xì)胞療法,它能成功嗎?

這家生物科技公司力挺干細(xì)胞療法,它能成功嗎?

Sy Mukherjee 2019-06-03
Athersys的首席執(zhí)行官表示,干細(xì)胞領(lǐng)域受到的待遇并不公平。

以干細(xì)胞為基礎(chǔ)的醫(yī)學(xué)領(lǐng)域一直讓人相當(dāng)失望,還因夸大其詞遭到監(jiān)管譴責(zé)。但Athersys的首席執(zhí)行官吉爾·范·伯克倫表示,干細(xì)胞領(lǐng)域受到的待遇并不公平。

“說干細(xì)胞沒有真正發(fā)揮作用是一種誤解?!彼诓稍L中告訴《財(cái)富》雜志。 “現(xiàn)在干細(xì)胞是個(gè)非常熱門的領(lǐng)域,情況真的發(fā)生了變化。”

范·伯克倫介紹了公司的近期成果,包括一些中期、后期臨床試驗(yàn)的細(xì)胞療法。就在兩周前,Athersys的實(shí)驗(yàn)性干細(xì)胞療法MultiStem獲得了美國(guó)食品和藥物管理局(FDA)的快速審核資格,非常令人艷羨。該藥物可以用于治療名為急性呼吸窘迫綜合癥(ARDS)的嚴(yán)重肺衰竭疾病。獲得快速審核資格可以加速監(jiān)管審批過程,通常是在治療某種疾病藥品缺乏的情況下。

極為嚴(yán)重的急性呼吸窘迫綜合癥顯然屬于此類疾病。美國(guó)肺病協(xié)會(huì)(American Lung Association)稱,罹患該病的患者通常因?yàn)槟撤N嚴(yán)重傷害或疾病而引發(fā)肺部受創(chuàng),液體滲入肺部,導(dǎo)致病情已然嚴(yán)重的患者出現(xiàn)呼吸困難(或完全無法呼吸)。

Athersys對(duì)MultiStem采取的研究發(fā)現(xiàn),與安慰劑組相比,患者“確診患有急性呼吸窘迫綜合癥數(shù)天之內(nèi)接受治療并使用呼吸機(jī)后,死亡率降低,無需呼吸機(jī)的天數(shù)增加,無需進(jìn)入加護(hù)病房的天數(shù)增加”。初步治療結(jié)果推動(dòng)該藥進(jìn)入美國(guó)食品和藥物管理局的快速審批通道。

MultiStem療法的最吸引人之處是在名字里加入了“Multi”(意思是“多”——譯注)。范·伯克倫表示,Athersys正在努力避免許多干細(xì)胞領(lǐng)域新貴面臨的主要問題:可擴(kuò)展性和多用途。Athersys不要求個(gè)人捐獻(xiàn)者完美配型,而是希望提供“現(xiàn)成”的再生干細(xì)胞治療,幫助病患修復(fù)組織。

“這種藥的功能并不單一,而是同時(shí)具備多項(xiàng)功能。”范·伯克倫說。例如,該藥正在針對(duì)缺血性中風(fēng)患者進(jìn)行后期臨床實(shí)驗(yàn)(該項(xiàng)目也已經(jīng)獲得美國(guó)食品和藥物管理局的快速審核資格)?!案杉?xì)胞治療的市場(chǎng)機(jī)會(huì)比其他領(lǐng)域都大?!彼a(bǔ)充道。

Athersys到底能否在眾多公司的慘敗之處獲得成功,應(yīng)該很快就可以揭曉。(財(cái)富中文網(wǎng))

譯者:馮豐

審校:夏林

The world of stem cell-based medicine has had its fair share of disappointments and regulatory recriminations over wildly inflated claims. But Athersys CEO Gil Van Bokkelen says the stem cell field isn’t getting a fair shake.

“It’s a misconception to say stem cells haven’t really delivered,” he tells Fortune in an interview. “This is a very hot field right now, and things have really changed.”

Van Bokkelen points to his own company’s recent achievements, including a number of cell therapies in mid- or late-stage clinical trials. Just two weeks ago, Athersys’ experimental MultiStem treatment received the Food and Drug Administration’s (FDA) coveted fast track designation in a devastating lung-wasting disease called acute respiratory distress syndrome (ARDS). These designations speed the regulatory process and is typically granted for products that treat disorders with a dearth of available treatments.

And devastating ARDS surely is. It’s a consequence of trauma to the lungs in patients who are typically already in the hospital for some kind of severe injury or illness, and it results in fluid leaking in to the lungs, making the very act of breathing even more difficult (or impossible) in patients who are already extremely sick, according to the American Lung Association.

Athersys’ studies of MultiStem found that patients who received the treatment “within several days after being diagnosed with ARDS and being placed on a ventilator experienced lower mortality, increased ventilator-free days, and increased ICU-free days” compared to a placebo group. Those preliminary results led to the FDA fast track.

What makes the MultiStem platform intriguing is, well, what puts the “Multi” in the name. Van Bokkelen says that Athersys is trying to avoid the main problem many stem cell upstarts face: Scaleability and multi-faceted uses. Rather than requiring an individual, perfect donor match, Athersys is attempting to create a product that’s an “off-the-shelf” version of regenerative stem cell treatment that can help repair tissue.

“The drug isn’t just doing one thing, it’s doing a bunch of different things,” says Van Bokkelen. For instance, it’s being tested out in late-stage trials for ischemic stroke patients (yet another program with FDA fast track designation). “Market opportunity is way bigger in this space than pretty much any other one,” he adds.

We should find out soon enough whether Athersys can succeed where so many others have failed.

掃描二維碼下載財(cái)富APP
国产乱子伦三级在线播放| 欧美黑人日韩三级破处女视频污片| 柠檬AV导航国产精品久久久| 久久中文骚妇内射| 日本熟妇在线手机视频| 男人j进入女人j内部免费网站| 色AV永久无码影院AV| 97se狠狠狠狠狼鲁亚洲综合色| 成人国产精品久久久免费| 无码粉嫩虎白一线天在线观看| 国产欧美综合在线观看| 激情国产精品视频一区二区| 极品美女国产精品免费一区| 久久久不卡国产精品一区二区欧美| 重口SM一区二区三区视频| 日韩人妻熟精品久久无码少年阿宾| 顶级欧美熟妇高清xxxxx| 2021777久久人妻少妇嫩草AV| 欧美性videos高清精品| 97日日碰人人模人人澡| 欧美综合自拍亚洲图久青草| 亚洲熟女精品一区二区成人| 免费无码不卡视频在线观看| 免费看成人毛片无码视频| 精品国产福利91一区二区三区| 少妇高潮太爽了在线视频| 噼里啪啦免费高清看| 国产成人无码免费看片软件| 免费看片A级毛片免费看| 无码熟妇人妻AV国产精品交换| 亚洲AV永久无码精品网站| 国内一级一片内射免费视频观看| 国产又粗又猛又黄又爽无遮挡| 国产无码在线免费大片| 久久久久人妻一区精品色| 成人乱人伦精品小说| 亚洲精品无码久久久久去Q| 欧美精品久久久久久精品爆乳| 国产精品亚洲一区二区三区z| 亚洲av无码a片在线观看| 国产成年无码av片在线韩国|